CD4-positive diffuse large B-cell lymphoma: A variant with aggressive clinical potential

Table 2 Summary of ALK-negative, CD4-positive diffuse large B-cell lymphomas reported in the literature

Case no.	Age/sex	Diagnosis	Immunophenotype	Molecular findings	Gross description	Treatment	Clinical outcome	Site	Stage	Ref.
1	81/F	DLBCL	CD19, CD4, CD7				Lost to follow-up after 13 mo of stable disease	N/A	III	[2]
2	82/M	DLBCL	CD4+, CD5+, CD19+, CD20+, CD23+, CD25+, kappa+			R-CHOP × 5	Complete remission after chemotherapy	Left cervical and left inguinal lymph node		[11]
3	55/F	DLBCL	CD20 (weak), BCL2, PAX5, surface kappa, MUM1, and CD4	Clonal IgH gene rearrangement and no BCL2 gene rearrangement	Uniformly soft, greyish tissue	Mega Chop; R- Mega CHOP × 5	Complete remission after chemotherapy	Ileum		[6]
4	73/M	DLBCL	CD45 (dim), CD19, PAX5, CD20, CD10, BCL6, BCL2, surface lambda light chain, and CD4	Clonal IgH gene rearrangement and a BCL2 gene rearrangement		Adjuvant chemotherapy		Ileum		[6]

CD: Cluster of differentiation; DLBCL: Diffuse large B-cell lymphoma; F: Female; M: Male; N/A: Not available; CHOP: Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, mega.